Stocks of Cronos Group Inc (NASDAQ:CRON) traded higher last session on Wall Street, down -4.51% to $2.75.
CRON stock price is now 24.94% away from the 50-day moving average and 36.48% away from the 200-day moving average. The market capitalization of the company currently stands at $1.05B.
With the price target of $3, Bernstein recently initiated with Mkt Perform rating for Cronos Group Inc (NASDAQ: CRON). , while ‘CIBC’ rates the stock as ‘Sector Outperform’
In other news, ADLER JASON MARC, Director bought 37,500 shares of the company’s stock on May 30 ’23. The stock was bought for $65,074 at an average price of $1.74. Upon completion of the transaction, the Director now directly owns 1,402,304 shares in the company, valued at $3.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25 ’23, Director ADLER JASON MARC bought 100,000 shares of the business’s stock. A total of $179,650 was incurred on buying the stock at an average price of $1.80. This leaves the insider owning 1,376,054 shares of the company worth $3.78 million. A total of 47.86% of the company’s stock is owned by insiders.
During the past 12 months, Cronos Group Inc has had a low of $1.64 and a high of $2.90. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 22.54, and a quick ratio of 21.81. The fifty day moving average price for CRON is $2.2010 and a two-hundred day moving average price translates $2.0149 for the stock.
The latest earnings results from Cronos Group Inc (NASDAQ: CRON) was released for Dec, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.05, missing analysts’ expectations of -$0.01 by -0.04. This compares to -$0.02 EPS in the same period last year. The net profit margin was -84.02% and return on equity was -6.34% for CRON. The company reported revenue of $23.27 million for the quarter, compared to $19.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.07 percent. For the current quarter, analysts expect CRON to generate $23.78M in revenue.
Cronos Group Inc(CRON) Company Profile
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
